同义名 :	Risedronic acid; Risedronate; NE 58019
	CAS号 :	105462-24-6
	货号 :	A471285
	分子式 :	C7H11NO7P2
	纯度 :	99% HPLC
	分子量 :	283.11
	MDL号 :	MFCD00867080
	存储条件：	Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Risedronate (Risedronic acid) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption. Risedronate is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis[3]. In experimental models of osteoporosis, risedronate inhibited bone loss and improved trabecular architecture[4]. Higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone[5]. Risedronate againsts blood stages of Plasmodium falciparum (50% inhibitory concentration [IC50] of 20.3±1.0 μM). Risedronate leads to an 88.9% inhibition of the rodent parasite Plasmodium berghei in mice on the seventh day of treatment; however, risedronate treatment did not result in a general increase of survival rates[6].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01907269	Osteoporosis	Not Applicable	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35205 United States, California Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Massachusetts University of Massachusetts at Worcester Worcester, Massachusetts, United States, 01655 United States, New York New York University New York, New York, United States, 10016 United States, Ohio Jewish Hospital of Cincinnati Cincinnati, Ohio, United States, 45236 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Washington Group Health Research Institute Seattle, Washington, United States, 98101 收起 <<
NCT01907269	-		Completed	-	-
NCT02155595	-		Active, not recruiting	August 2018	United States, Michigan ... 展开 >> Henry Ford Medical Center, New Center One Detroit, Michigan, United States, 48202 收起 <<

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	3.53mL 0.71mL 0.35mL	17.66mL 3.53mL 1.77mL	35.32mL 7.06mL 3.53mL

参考文献

[1]Jordão FM, Saito AY, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. [2]Giljević Z, Vlak T. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety] . Reumatizam. 2006;53(2):66-71. Review. Croatian. [3]Giljević Z, Vlak T. Brzina, ucinkovitost i sigurnost risedronata u lijecenju osteoporoze [Treatment of osteoporosis by risedronate-- speed, efficacy and safety]. Reumatizam. 2006;53(2):66-71. Croatian [4]Goa KL, Balfour JA. Risedronate. Drugs Aging. 1998 Jul;13(1):83-91; discussion 92 [5]Iwamoto J, Takeda T, Sato Y, Matsumoto H. Effects of risedronate on osteoarthritis of the knee. Yonsei Med J. 2010 Mar;51(2):164-70 [6]Jordão FM, Saito AY, Miguel DC, de Jesus Peres V, Kimura EA, Katzin AM. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31